
Opinion|Videos|January 17, 2024
Key Takeaways from ASH 2023 in Myelofibrosis and AML
Following their review of updates from clinical trials presented at ASH 2023, the Oncology Brothers provide their key takeaways on recent data in myelofibrosis and acute myeloid leukemia.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















